These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35579627)

  • 41. To treat or not to treat: CFTR modulators after lung transplantation.
    Hayes D; Darland LK; Hjelm MA; Mansour HM; Wikenheiser-Brokamp KA
    Pediatr Transplant; 2021 Jun; 25(4):e14007. PubMed ID: 33742748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis.
    Silva Filho LVRFD; Athanazio RA; Tonon CR; Ferreira JC; Tanni SE
    J Bras Pneumol; 2024; 49(6):e20230187. PubMed ID: 38198345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.
    Gramegna A; Contarini M; Bindo F; Aliberti S; Blasi F
    Curr Opin Pharmacol; 2021 Apr; 57():81-88. PubMed ID: 33582393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
    J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

  • 47. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor.
    Ferreira FC; Buarque CD; Lopes-Pacheco M
    Molecules; 2024 Feb; 29(4):. PubMed ID: 38398574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
    Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M
    Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
    Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
    Chun SW; Somers ME; Burgener EB
    Curr Opin Pediatr; 2024 Jun; 36(3):290-295. PubMed ID: 38411576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy.
    Fortner CN; Seguin JM; Kay DM
    J Cyst Fibros; 2021 Sep; 20(5):835-836. PubMed ID: 33846105
    [No Abstract]   [Full Text] [Related]  

  • 54. Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.
    FitzMaurice TS; Nazareth D; Iyer K; Walshaw M; Al-Aloul M
    Exp Clin Transplant; 2022 Apr; 20(4):433-435. PubMed ID: 35297329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor/Tezacaftor/Ivacaftor.
    McParland C; Nunn M; Marras TK; Chiasson M
    J Cyst Fibros; 2024 Jan; 23(1):38-40. PubMed ID: 37076409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
    Burgener EB; Moss RB
    Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
    [No Abstract]   [Full Text] [Related]  

  • 58. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis.
    Bihler H; Sivachenko A; Millen L; Bhatt P; Patel AT; Chin J; Bailey V; Musisi I; LaPan A; Allaire NE; Conte J; Simon NR; Magaret AS; Raraigh KS; Cutting GR; Skach WR; Bridges RJ; Thomas PJ; Mense M
    J Cyst Fibros; 2024 Jul; 23(4):664-675. PubMed ID: 38388235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
    Hoy SM
    Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.